- Avecho Biotechnology (AVE) expands its collaboration with the Lambert Initiative to investigate its cannabidiol (CBD) soft-gel capsule in two more clinical trials
- AVE says the Australian cannabinoid therapeutics research group will examine the product in “novel” indications that may be treatable using CBD
- These candidate indications come from pre-clinical and early-stage clinical studies completed by Lambert researchers
- Avecho and Lambert have already submitted the protocol for the first trial for ethics approval, with first patients to be dosed in the middle of the year
- The second trial will being in the third quarter of this year
- Shares in Avecho Biotechnology are up 11.11 per cent to one cent at 11:27 am AEDT
Avecho Biotechnology (AVE) is expanding its collaboration with the Lambert Initiative to investigate its cannabidiol (CBD) soft-gel capsule in two more clinical trials.
The company this morning said the Australian cannabinoid therapeutics research group would examine the soft-gel product in “novel” indications that may be treatable using CBD.
The parties previously collaborated for a phase two clinical trial examining the use of a topical CBD tocopherol phosphate mixture (TPM) gel for the treatment of osteoarthritis of the fingers and hands.
A larger topical CBD trial is now being planned for 2023, along with a study to examine a topical cannabigerol (CBG) TPM product.
While Avecho said it would focus its efforts on its phase three clinical trial testing the CBD soft-gel capsule in an insomnia indication, the Lambert Initiative trials will test the product on a series of “novel” candidate indications not previously associated with CBD therapy.
These candidate indications come from pre-clinical and early-stage clinical studies completed by Lambert researchers.
“While our company remains principally focused on the upcoming phase three trial of our oral CBD soft-gel product, it has always been our intention to allow others to examine further clinical applications of our formulations in other indications of value and interest,” Avecho CEO Paul Gavin said.
“[The Lambert Initiative’s] decision to use Avecho’s CBD product in their own studies is a testament to the clinical relevance of the work we’ve conducted over the last three years on product development in the cannabinoid space,” Dr Gavin said.
The protocol for the first trial has been submitted for ethics approval, with the aim to dose patients in the middle of the year. The second study will then commence dosing during Q3 2023.
With the addition of the further Lambert Initiative studies, Avecho’s products will be used in seven clinical trials during 2023.
Avecho’s proprietary oral CBD soft-gel capsule is enhanced by its proprietary TPM technology to increase absorption, which the company described as a “major limitation” of existing cannabinoid therapy.
Shares in Avecho Biotechnology were up 11.11 per cent to one cent at 11:27 am AEDT.